Literature DB >> 8314307

Growth inhibition of human melanoma-derived cells by 12-O-tetradecanoyl phorbol 13-acetate.

Y Arita1, K R O'Driscoll, I B Weinstein.   

Abstract

In vitro growth of 6 human melanoma-derived cell lines was inhibited markedly by the phorbol-ester tumor promoter 12-O-tetradecanoyl phorbol 13-acetate (TPA), a potent activator of several isoforms of protein kinase C (PKC). Utilizing PKC isoform-specific antibodies in immunoblotting experiments, we found that the PKC alpha and PKC epsilon isoforms were expressed in all of the 6 melanoma cell lines tested, whereas the PKC beta isoform was expressed at detectable levels in only 2 of the 6 cell lines. The SK-Mel-173 melanoma cell line, which had relatively high levels of PKC beta mRNA and protein expression, and which was also the most sensitive to cell growth inhibition by TPA, was used to isolate clones whose growth was less inhibited by TPA. Immunoblotting experiments revealed that in parental SK-Mel 173 cells PKC beta was rapidly down-regulated to below detectable levels after treatment for 48 hr with TPA, but that in TPA-resistant variant clones there was negligible down-regulation of PKC beta by TPA. On the other hand, treatment of parental and TPA-resistant SK-Mel 173 cells with TPA led to partial down-regulation of PKC alpha in both cell lines. Total PKC enzyme activity was also greater in TPA-resistant cells than in parental SK-Mel 173 cells. Our results show that TPA might inhibit the growth of melanoma cells by causing down-regulation of specific isoforms of PKC that are required to maintain the growth of these cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8314307     DOI: 10.1002/ijc.2910560215

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity.

Authors:  Z T Han; X X Zhu; R Y Yang; J Z Sun; G F Tian; X J Liu; G S Cao; H L Newmark; A H Conney; R L Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 2.  Anti-cancer activities of Schedule E1 drugs used in ayurvedic formulations.

Authors:  E N T Vikram; R Ilavarasan; R Kamaraj
Journal:  J Ayurveda Integr Med       Date:  2022-05-31

3.  The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells.

Authors:  Sharon A Mason; Sarah-Jane Cozzi; Carly J Pierce; Sandra J Pavey; Peter G Parsons; Glen M Boyle
Journal:  Invest New Drugs       Date:  2009-07-28       Impact factor: 3.850

4.  12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s).

Authors:  Masahiro Oka; Naoko Sumita; Masanobu Sakaguchi; Tetsushi Iwasaki; Toshinori Bito; Toshiro Kageshita; Ken-ichi Sato; Yasuo Fukami; Chikako Nishigori
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

Review 5.  Understanding signaling cascades in melanoma.

Authors:  Pablo Lopez-Bergami; Boris Fitchman; Ze'ev Ronai
Journal:  Photochem Photobiol       Date:  2007-12-15       Impact factor: 3.421

6.  Comparative toxicity, phytochemistry, and use of 53 Philippine medicinal plants.

Authors:  Lydia M Clemen-Pascual; Rene Angelo S Macahig; Nina Rosario L Rojas
Journal:  Toxicol Rep       Date:  2021-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.